the source pile ~ every clipping's origin

Thymulin References

Every quantitative claim on this site is clipped from one of the studies below. Each entry carries a PubMed link and, where one exists, a DOI.

About this list

These are the primary sources behind the thymulin digest — peer-reviewed journal articles and reviews indexed in PubMed. The chemistry papers (Dardenne 1982, Dardenne 1994) and the human zinc-deficiency study (Prasad 1988) anchor the established findings; the model-based work (Novoselova 2014, da Silva 2020, the Lunin EAE studies) and the 1980s human-trial record (the open FTS-Zn trial and the controlled nonathymulin trials) are cited exactly where they appear in the text. Numbers match the inline markers throughout the site.

How to weigh these entries

Not all of these clippings carry the same weight, and it helps to read the list with that in mind. The strongest are the mechanism studies and the human zinc-deficiency work: a remove-and-restore zinc experiment [1], a conformation-and-zinc-status review [2], and a controlled human zinc-deficiency study [3]. Those are the load-bearing parts of the record.

The disease-model entries — the LPS-inflammation, EAE, asthma-gene-therapy, diabetes, radioprotection and steroidogenesis studies — are real and often striking, but they live in mice, swine, or cultured cells, and we cite them as such [6][7][9][10][11][13]. The human-trial entries are the oldest and thinnest: a small open trial of FTS-Zn [8] and two placebo-controlled trials of the analog nonathymulin [14], plus an in-vitro patient-cell study [12]. Reviews [4][5] are useful syntheses but are not themselves primary data. Read each entry for what it is, follow the link, and check the species before you trust the headline.

  1. Dardenne M, Pléau JM, Nabarra B, Lefrancier P, Derrien M, Choay J, Bach JF. Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proc Natl Acad Sci U S A. 1982;79(17):5370-3.
  2. Dardenne M, Pleau JM. Interactions between zinc and thymulin. Met Based Drugs. 1994;1(2-3):233-9.
  3. Prasad AS, Meftah S, Abdallah J, Kaplan J, Brewer GJ, Bach JF, Dardenne M. Serum thymulin in human zinc deficiency. J Clin Invest. 1988;82(4):1202-10.
  4. Reggiani PC, Morel GR, Cónsole GM, Barbeito CG, Rodriguez SS, Brown OA, Bellini MJ, Pléau JM, Dardenne M, Goya RG. The thymus-neuroendocrine axis: physiology, molecular biology, and therapeutic potential of the thymic peptide thymulin. Ann N Y Acad Sci. 2009;1153:98-106.
  5. Reggiani PC, Schwerdt JI, Console GM, Roggero EA, Dardenne M, Goya RG. Physiology and therapeutic potential of the thymic peptide thymulin. Curr Pharm Des. 2014;20(29):4690-6.
  6. Novoselova EG, Khrenov MO, Glushkova OV, Lunin SM, Parfenyuk SB, Novoselova TV, Fesenko EE. Anti-inflammatory effects of IKK inhibitor XII, thymulin, and fat-soluble antioxidants in LPS-treated mice. Mediators Inflamm. 2014;2014:724838.
  7. da Silva AL, de Oliveira GP, Kim N, Cruz FF, Kitoko JZ, Blanco NG, Martini SV, Hanes J, Rocco PRM, Suk JS, Morales MM. Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma. Sci Adv. 2020;6(24):eaay7973.
  8. Faure GC, Bene MC, Thomas P, Tamisier JN. An open trial of thymulin (FTS-Zn) in rheumatoid arthritis patients: sequential clinical and immunological follow-up. Clin Exp Rheumatol. 1987;5(3):291-3.
  9. Lunin SM, Novoselova EG, Glushkova OV, Parfenyuk SB, Kuzekova AA, Novoselova TV, Sharapov MG, Mubarakshina EK. Protective effect of exogenous peroxiredoxin 6 and thymic peptide thymulin on BBB conditions in an experimental model of multiple sclerosis. Arch Biochem Biophys. 2023;746:109729.
  10. Lunin SM, Khrenov MO, Novoselova TV, Parfenyuk SB, Glushkova OV, Fesenko EE, Novoselova EG. Modulation of inflammatory response in mice with severe autoimmune disease by thymic peptide thymulin and an inhibitor of NF-kappaB signalling. Int Immunopharmacol. 2015;25(2):260-6.
  11. Kobayashi H, Abe H, Ueyama T, Awaya A, Shikita M. Radioprotective effects of serum thymic factor in mice. Radiat Res. 1992;129(3):351-6.
  12. Faure G, Bene MC, Tamisier JN, Gaucher A, Duheille J. Thymulin (FTS-Zn) induced in vitro modulation of T cell subsets markers on lymphocytes from rheumatoid arthritis and systemic lupus erythematosus patients. Int J Immunopharmacol. 1984;6(4):381-8.
  13. Wise T, Ford JJ. Effects of the thymic peptide thymulin on in vitro and in vivo testicular steroid concentrations in white composite and Meishan boars. J Anim Sci. 1999;77(8):2240-51.
  14. Amor B, Dougados M, Mery C, Dardenne M, Bach JF. Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials. Ann Rheum Dis. 1987;46(7):549-54.
  15. Wang W, Thomas R, Oh J, Su DM. Thymic Aging May Be Associated with COVID-19 Pathophysiology in the Elderly. Cells. 2021;10(3):628.